On Monday, H.C. Wainwright maintained a Buy rating on Rockwell Medical (NASDAQ:RMTI) Technologies (NASDAQ:RMTI) with a steady price target of $7.00. Currently trading at $2.08, the stock sits well below analysts' consensus target range of $6.00-$7.00.
According to InvestingPro analysis, the company maintains a GREAT financial health score despite current profitability challenges. The firm's endorsement follows a recent announcement by Rockwell Medical (TASE:PMCN) that it has entered into a product purchase agreement with a top global provider of dialysis products and services.
Rockwell Medical, recognized as the principal supplier of liquid bicarbonate in the United States and the only manufacturer capable of producing it at a scale to support major U.S.-based dialysis providers, will supply its liquid bicarbonate hemodialysis concentrate, SteriLyte, under the three-year agreement. This deal also includes the option for two additional one-year renewals.
The new agreement is anticipated to generate over $10 million in net sales for Rockwell Medical in the first year alone, with subsequent annual price increases. Notably, this expected revenue was not fully accounted for in the company's previously announced revenue projections for 2025. This new contract could further accelerate the company's impressive 22.37% revenue growth seen in the last twelve months, while maintaining its healthy current ratio of 2.41x.
H.C. Wainwright highlights that this agreement could provide a layer of security for Rockwell Medical's future revenue streams. The firm also points out that Rockwell Medical is actively seeking to bridge a projected revenue shortfall through various strategies, including securing new contracts with higher margins, establishing product and distribution agreements, implementing standard price increases, and exploring new hemodialysis product opportunities.
The analyst firm believes that the recent product purchase agreement is a key step in Rockwell Medical's strategy to diversify its portfolio and secure its financial position. The reaffirmed Buy rating and $7.00 price target reflect the firm's positive outlook on Rockwell Medical's prospects following this significant development. For deeper insights into RMTI's valuation and growth potential, including additional ProTips and comprehensive financial analysis, investors can access the full company research report on InvestingPro.
In other recent news, Rockwell Medical secured a substantial product purchase agreement with a leading global dialysis product and service provider, set to contribute more than $10 million in net sales in the first year. The deal surpasses the company's previous sales projections for 2025. Rockwell Medical also announced the appointment of Jesse Neri as its new Senior Vice President and Chief Financial Officer.
Furthermore, H.C. Wainwright reduced the stock price target for Rockwell Medical from $9.00 to $7.00, while maintaining a Buy rating, following the company's Q3 results and an expected decrease in future order volumes from a key customer. Rodman & Renshaw initiated coverage on the company's stock with a Buy rating, citing the company's potential for growth in the U.S. dialysis concentrate market.
Rockwell Medical also announced a $25 million common stock offering in collaboration with Cantor Fitzgerald & Co., aiming to raise capital for various corporate purposes. Despite a projected decline in net sales for 2025 due to a reduction in orders from a major customer, Rockwell Medical is actively pursuing new contracts to offset potential revenue declines.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.